TABLE 2.
TRAP A-domain vaccine constructs testeda
| Expt | Vaccine | Adjuvant | Parasite rRNA (group avg [±SD])c | Antibody titerd
|
|
|---|---|---|---|---|---|
| ELISA | IF | ||||
| 1 | TGGB1 | None | 3.4 (0.7) | 1:104–105 | 1:10–102 |
| Control | None | 2.7 (1.1) | |||
| 2 | TGGB1 | TiterMax | 5.1 (0.6) | 1:103–105 | 1:10–102 |
| Control | TiterMax | 5.5 (0.3) | |||
| 3 | TGGB1 | QS-21 | 3.4 (1.0) | 1:104–105 | 1:10–102 |
| Control | QS-21 | 3.4 (0.6) | |||
| 4 | TGGB1 | Freund'sb | 12.4 (2.4) | 1:104–105 | 1:10–102 |
| Control | Freund's | 11.4 (1.7) | |||
| HbcAg-B1 | Freund's | 11.7 (1.8) | 1:104–105 | 1:10–102 | |
| HbcAg (control) | Freund's | 11.9 (1.5 | |||
| 5 | TGGB3 | None | 4.6 (1.0) | 1:104–105 | |
| Control | None | 4.3 (1.3) | |||
a
Groups of eight mice were immunized and then challenged with 104 P. yoelii sporozoites/mouse.
b
The initial injections were performed with complete Freund's adjuvant, and the boosters were done with incomplete Freund's adjuvant.
c
Values indicate the group averages (± the standard deviations) of parasite rRNA.
d
Titers represent the range within each group. ELISAs were performed against the peptide, B1 or B3, that is present in the antigen used for immunization. IF labeling was performed on air-dried P. yoelii sporozoites.